| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01001598 | Fanconi Anemia|Dyskeratosis Congenita | Drug: danazol | Boston Children Hospital | Phase 1|Phase 2 | 2009-11-01 | 2014-09-12 |
| NCT01779232 | Endometriosis|Ovarian Cysts|Infertility | Drug: Danazol|Drug: placebo | Centre for Endocrinology and Reproductive Medicine, Italy | Phase 4 | 2012-10-01 | 2016-04-25 |
| NCT00953771 | Thrombotic Thrombocytopenic Purpura | Drug: Danazol | Beth Israel Medical Center|Icahn School of Medicine at Mount Sinai | Phase 2 | 2008-10-01 | 2016-11-22 |
| NCT01667263 | Autoimmune Thrombocytopenia | Drug: All-trance retinoid acid|Drug: Danazol | Peking University People's Hospital|Beijing Municipal Science & Technology Commission|Beijing Hospital|Qilu Hospital|Navy General Hospital, Beijing|Beijing Tongren Hospital | Phase 2 | 2012-06-01 | 2017-02-24 |
| NCT01732445 | Anemia|Primary Myelofibrosis|Secondary Myelofibrosis | Drug: ruxolitinib phosphate|Drug: danazol|Other: quality-of-life assessment|Other: questionnaire administration | Mayo Clinic|National Cancer Institute (NCI) | Phase 2 | 2013-04-01 | 2016-08-25 |
| NCT00003946 | Endometrial Cancer | Drug: danazol | Gynecologic Oncology Group|National Cancer Institute (NCI) | Phase 2 | 1999-08-01 | 2013-06-07 |
| NCT00744276 | Fibrocystic Disease of Breast | Drug: danazol|Drug: Placebo | FemmePharma Global Healthcare, Inc. | Phase 2 | 2007-01-01 | 2010-05-25 |
| NCT01441037 | Aplastic Anemia | Drug: Danazol | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) | Phase 1|Phase 2 | 2011-07-15 | 2017-01-24 |
| NCT01821677 | Diabetic Macular Edema | Drug: Low Dose Danazol|Drug: Placebo | Ampio Pharmaceuticals. Inc. | Phase 3 | 2013-02-01 | 2016-05-04 |
| NCT01162941 | Thrombocytopenia | Other: Steroid refractory ITP | Cooperative Study Group A for Hematology | Phase 2 | 2010-02-01 | 2010-07-14 |
| NCT02002403 | Diabetic Macular Edema | Drug: Danazol | St. Michael's Hospital, Toronto | Phase 2 | 2011-01-01 | 2013-12-05 |
| NCT01105793 | Moderate to Severe Cyclic Mastalgia | Drug: Danazol | FemmePharma Global Healthcare, Inc. | Phase 2 | 2010-06-01 | 2011-10-25 |
| NCT00758953 | Endometriosis | Drug: Danazol Once Weekly|Drug: Danazol Twice Weekly|Drug: Placebo Once Weekly|Drug: Placebo Twice Weekly | Lumara Health, Inc. | Phase 2 | 2007-02-01 | 2012-03-02 |
| NCT02556411 | Adenomyosis|Chronic Pelvic Pain | Drug: LNG-IUS 13,5 mg Levonorgestrel|Drug: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg | University of Cagliari | | 2016-06-01 | 2016-03-08 |
| NCT02201719 | Adenomyosis | | Oslo University Hospital|Helse Sor-Ost | | 2014-07-01 | 2016-09-14 |
| NCT02197923 | Adenomyosis | Procedure: Myometrial biopsy|Procedure: endometrial biopsy | Oslo University Hospital|University of Oslo|Helse Sor-Ost | | 2014-07-01 | 2016-09-14 |
| NCT02599077 | Endometriosis | Drug: Dienogest|Drug: Levonorgestrel | Fundaci贸n Santa Fe de Bogota | Phase 2|Phase 3 | 2015-11-01 | 2016-11-21 |
| NCT00155051 | Endometriosis | | National Taiwan University Hospital | | 2004-07-01 | 2005-09-09 |
| NCT01071954 | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Biological: Romiplostim | Amgen | Phase 3 | 2009-12-01 | 2017-01-25 |
| NCT01438840 | Chronic Thrombocytopenia|Immune Thrombocytopenia | Drug: Avatrombopag|Drug: Placebo|Drug: Standard of care | Eisai Inc. | Phase 3 | 2012-02-01 | 2016-12-12 |
| NCT01773187 | Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis | Drug: Pacritinib|Drug: Best Available Therapy | CTI BioPharma | Phase 3 | 2012-12-01 | 2016-12-15 |
| NCT02055781 | Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis | Drug: Pacritinib|Drug: Best Available Therapy | CTI BioPharma | Phase 3 | 2013-12-01 | 2016-12-15 |
